A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary) ; Nogapendekin alfa inbakicept (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Altor BioScience Corporation
- 20 Sep 2024 According to ClinicalTrials.gov, this Study is (terminated )halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- 20 Sep 2024 Status changed from active, no longer recruiting to discontinued.
- 19 Jan 2018 Planned End Date changed from 1 Jan 2020 to 1 Oct 2020.